Tislelizumab + cisplatin + paclitaxel
No. XJTU1AF2022LSK-374
Approved small_molecule active
Quick answer
Tislelizumab + cisplatin + paclitaxel for Esophageal Squamous Cell Carcinoma is a Approved program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Esophageal Squamous Cell Carcinoma
- Phase
- Approved
- Modality
- small_molecule
- Status
- active